share_log

Guangzhou Kingmed Diagnostics Group (SHSE:603882) Has A Pretty Healthy Balance Sheet

Guangzhou Kingmed Diagnostics Group (SHSE:603882) Has A Pretty Healthy Balance Sheet

廣州金邁診斷集團(SHSE: 603882)的資產負債表相當不錯
Simply Wall St ·  02/07 18:28

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know worries about.' It's only natural to consider a company's balance sheet when you examine how risky it is, since debt is often involved when a business collapses. We note that Guangzhou Kingmed Diagnostics Group Co., Ltd. (SHSE:603882) does have debt on its balance sheet. But is this debt a concern to shareholders?

霍華德·馬克斯說得好,他說的不是擔心股價的波動,而是 “永久損失的可能性是我擔心的風險... 也是我認識的每位實際投資者所擔心的風險。”當你檢查公司的資產負債表的風險時,考慮它的資產負債表是很自然的,因爲企業倒閉時通常會涉及債務。我們注意到,廣州金邁診斷集團有限公司(SHSE: 603882)的資產負債表上確實有債務。但是這筆債務是股東關心的問題嗎?

What Risk Does Debt Bring?

債務會帶來什麼風險?

Generally speaking, debt only becomes a real problem when a company can't easily pay it off, either by raising capital or with its own cash flow. If things get really bad, the lenders can take control of the business. However, a more frequent (but still costly) occurrence is where a company must issue shares at bargain-basement prices, permanently diluting shareholders, just to shore up its balance sheet. Of course, the upside of debt is that it often represents cheap capital, especially when it replaces dilution in a company with the ability to reinvest at high rates of return. When we think about a company's use of debt, we first look at cash and debt together.

一般而言,只有當公司無法通過籌集資金或使用自己的現金流輕鬆還清債務時,債務才會成爲真正的問題。如果情況變得非常糟糕,貸款人可以控制業務。但是,更常見(但成本仍然很高)的情況是,公司必須以低廉的價格發行股票,永久稀釋股東,只是爲了支撐其資產負債表。當然,債務的好處是它通常代表廉價資本,尤其是當它取代了具有高回報率再投資能力的公司的稀釋時。當我們考慮公司使用債務時,我們首先將現金和債務放在一起看。

How Much Debt Does Guangzhou Kingmed Diagnostics Group Carry?

廣州金邁診斷集團揹負了多少債務?

The chart below, which you can click on for greater detail, shows that Guangzhou Kingmed Diagnostics Group had CN¥368.1m in debt in September 2023; about the same as the year before. But it also has CN¥2.06b in cash to offset that, meaning it has CN¥1.69b net cash.

您可以點擊下圖查看更多詳情,該圖表顯示,廣州金邁診斷集團在2023年9月的債務爲3.681億元人民幣;與前一年大致相同。但它也有20.6億元人民幣的現金來抵消這一點,這意味着它的淨現金爲16.9億元人民幣。

debt-equity-history-analysis
SHSE:603882 Debt to Equity History February 7th 2024
SHSE: 603882 2024 年 2 月 7 日債務與股權比率的歷史記錄

How Strong Is Guangzhou Kingmed Diagnostics Group's Balance Sheet?

廣州金邁診斷集團的資產負債表有多強?

Zooming in on the latest balance sheet data, we can see that Guangzhou Kingmed Diagnostics Group had liabilities of CN¥2.95b due within 12 months and liabilities of CN¥539.7m due beyond that. Offsetting these obligations, it had cash of CN¥2.06b as well as receivables valued at CN¥6.19b due within 12 months. So it actually has CN¥4.76b more liquid assets than total liabilities.

放大最新的資產負債表數據,我們可以看到,廣州金邁診斷集團在12個月內到期的負債爲29.5億元人民幣,之後到期的負債爲5.397億元人民幣。除這些債務外,它有20.6億元人民幣的現金以及價值61.9億元人民幣的應收賬款將在12個月內到期。所以它實際上有4.76億元人民幣 更多 流動資產超過總負債。

It's good to see that Guangzhou Kingmed Diagnostics Group has plenty of liquidity on its balance sheet, suggesting conservative management of liabilities. Given it has easily adequate short term liquidity, we don't think it will have any issues with its lenders. Simply put, the fact that Guangzhou Kingmed Diagnostics Group has more cash than debt is arguably a good indication that it can manage its debt safely.

很高興看到廣州金邁診斷集團的資產負債表上有充足的流動性,這表明對負債的管理比較保守。鑑於它很容易獲得足夠的短期流動性,我們認爲其貸款機構不會有任何問題。簡而言之,廣州金邁診斷集團的現金多於債務,這一事實可以說是一個很好的跡象,表明它可以安全地管理債務。

In fact Guangzhou Kingmed Diagnostics Group's saving grace is its low debt levels, because its EBIT has tanked 83% in the last twelve months. When it comes to paying off debt, falling earnings are no more useful than sugary sodas are for your health. When analysing debt levels, the balance sheet is the obvious place to start. But it is future earnings, more than anything, that will determine Guangzhou Kingmed Diagnostics Group's ability to maintain a healthy balance sheet going forward. So if you're focused on the future you can check out this free report showing analyst profit forecasts.

實際上,廣州金邁診斷集團的救命之處在於其低債務水平,因爲其息稅前利潤在過去十二個月中下降了83%。在還清債務方面,收入下降對健康的作用並不比含糖的蘇打水更有用。在分析債務水平時,資產負債表是顯而易見的起點。但是,未來的收益將決定廣州金邁診斷集團未來維持健康資產負債表的能力。因此,如果您專注於未來,可以查看這份顯示分析師利潤預測的免費報告。

Finally, while the tax-man may adore accounting profits, lenders only accept cold hard cash. While Guangzhou Kingmed Diagnostics Group has net cash on its balance sheet, it's still worth taking a look at its ability to convert earnings before interest and tax (EBIT) to free cash flow, to help us understand how quickly it is building (or eroding) that cash balance. Looking at the most recent three years, Guangzhou Kingmed Diagnostics Group recorded free cash flow of 38% of its EBIT, which is weaker than we'd expect. That weak cash conversion makes it more difficult to handle indebtedness.

最後,儘管稅務人員可能喜歡會計利潤,但貸款人只接受冷硬現金。儘管廣州金邁診斷集團的資產負債表上有淨現金,但仍值得一看其將息稅前收益(EBIT)轉換爲自由現金流的能力,以幫助我們了解其建立(或侵蝕)現金餘額的速度有多快。從最近三年來看,廣州金邁診斷集團錄得的自由現金流佔其息稅前利潤的38%,低於我們的預期。這種疲軟的現金轉換使得處理債務變得更加困難。

Summing Up

總結

While it is always sensible to investigate a company's debt, in this case Guangzhou Kingmed Diagnostics Group has CN¥1.69b in net cash and a decent-looking balance sheet. So we don't have any problem with Guangzhou Kingmed Diagnostics Group's use of debt. When analysing debt levels, the balance sheet is the obvious place to start. However, not all investment risk resides within the balance sheet - far from it. Case in point: We've spotted 2 warning signs for Guangzhou Kingmed Diagnostics Group you should be aware of, and 1 of them is potentially serious.

儘管調查一家公司的債務總是明智的,但在本案中,廣州金邁診斷集團的淨現金爲16.9億元人民幣,資產負債表看起來不錯。因此,我們對廣州金邁診斷集團使用債務沒有任何問題。在分析債務水平時,資產負債表是顯而易見的起點。但是,並非所有的投資風險都存在於資產負債表中,遠非如此。一個很好的例子:我們已經發現了你應該注意的廣州金邁診斷集團的兩個警告信號,其中一個可能很嚴重。

If you're interested in investing in businesses that can grow profits without the burden of debt, then check out this free list of growing businesses that have net cash on the balance sheet.

如果你有興趣投資能夠在沒有債務負擔的情況下增加利潤的企業,請查看這份資產負債表上有淨現金的成長型企業的免費清單。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論